Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC1558646981;46982;46983 chr2:178618794;178618793;178618792chr2:179483521;179483520;179483519
N2AB1394542058;42059;42060 chr2:178618794;178618793;178618792chr2:179483521;179483520;179483519
N2A1301839277;39278;39279 chr2:178618794;178618793;178618792chr2:179483521;179483520;179483519
N2B652119786;19787;19788 chr2:178618794;178618793;178618792chr2:179483521;179483520;179483519
Novex-1664620161;20162;20163 chr2:178618794;178618793;178618792chr2:179483521;179483520;179483519
Novex-2671320362;20363;20364 chr2:178618794;178618793;178618792chr2:179483521;179483520;179483519
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: T
  • RefSeq wild type transcript codon: ACA
  • RefSeq wild type template codon: TGT
  • Domain: Ig-108
  • Domain position: 19
  • Structural Position: 29
  • Q(SASA): 0.3227
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
T/S rs764917649 -0.767 0.98 N 0.512 0.138 0.143124449307 gnomAD-2.1.1 4.05E-06 None None None None N None 0 0 None 0 0 None 0 None 0 0 1.67504E-04
T/S rs764917649 -0.767 0.98 N 0.512 0.138 0.143124449307 gnomAD-4.0.0 1.59713E-06 None None None None N None 0 0 None 0 0 None 0 0 0 0 3.04044E-05

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
T/A 0.1032 likely_benign 0.115 benign -0.622 Destabilizing 0.91 D 0.479 neutral N 0.460211243 None None N
T/C 0.4124 ambiguous 0.4225 ambiguous -0.437 Destabilizing 1.0 D 0.673 neutral None None None None N
T/D 0.403 ambiguous 0.4204 ambiguous 0.149 Stabilizing 0.999 D 0.645 neutral None None None None N
T/E 0.2516 likely_benign 0.278 benign 0.144 Stabilizing 0.999 D 0.64 neutral None None None None N
T/F 0.2297 likely_benign 0.27 benign -0.73 Destabilizing 0.996 D 0.714 prob.delet. None None None None N
T/G 0.3413 ambiguous 0.3808 ambiguous -0.866 Destabilizing 0.995 D 0.617 neutral None None None None N
T/H 0.246 likely_benign 0.2655 benign -1.076 Destabilizing 1.0 D 0.704 prob.neutral None None None None N
T/I 0.1282 likely_benign 0.1484 benign -0.072 Destabilizing 0.925 D 0.572 neutral N 0.457543516 None None N
T/K 0.2172 likely_benign 0.2383 benign -0.577 Destabilizing 0.998 D 0.642 neutral N 0.456446007 None None N
T/L 0.0966 likely_benign 0.1073 benign -0.072 Destabilizing 0.871 D 0.545 neutral None None None None N
T/M 0.0905 likely_benign 0.1039 benign 0.007 Stabilizing 0.996 D 0.703 prob.neutral None None None None N
T/N 0.134 likely_benign 0.1437 benign -0.5 Destabilizing 0.999 D 0.579 neutral None None None None N
T/P 0.3321 likely_benign 0.3364 benign -0.223 Destabilizing 0.998 D 0.695 prob.neutral N 0.462024896 None None N
T/Q 0.2032 likely_benign 0.2223 benign -0.613 Destabilizing 0.999 D 0.699 prob.neutral None None None None N
T/R 0.1907 likely_benign 0.2148 benign -0.372 Destabilizing 0.998 D 0.695 prob.neutral N 0.452189505 None None N
T/S 0.1261 likely_benign 0.1459 benign -0.789 Destabilizing 0.98 D 0.512 neutral N 0.457228874 None None N
T/V 0.1046 likely_benign 0.1184 benign -0.223 Destabilizing 0.155 N 0.245 neutral None None None None N
T/W 0.5693 likely_pathogenic 0.6032 pathogenic -0.698 Destabilizing 1.0 D 0.705 prob.neutral None None None None N
T/Y 0.258 likely_benign 0.2687 benign -0.445 Destabilizing 0.999 D 0.718 prob.delet. None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.